Sign in
Stories
Evaxion Biotech Closes Public Offering
Share
4P-Pharma Secures €15 Million Funding
AI-Powered Antigen Research Partnership
Advancements in Antibodies to Protect Im...
BioNTech's mRNA Cancer Vaccine Progress
Breakthrough Cancer Immunotherapy for Do...
Breakthrough Cancer Vaccine Shows Promis...
Overview
API
Evaxion Biotech A/S closes its public offering, raising $15 million for advancing its AI-Immunology™ platform and developing personalized oncology vaccines and therapies.
Ask a question
How does Evaxion Biotech's AI-Immunology™ platform differ from traditional vaccine development?
How might the advancement of personalized oncology therapies affect the healthcare industry and patient outcomes?
What potential impact could the successful funding have on the company's future growth and market position?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage